Everything tagged "fda" across research, earnings, and macro.
4 articles
Summit Therapeutics is a high-risk, high-upside oncology story built around ivonescimab, with positive Phase III data and an FDA review underway. The stock looks attractive for investors willing to accept binary regulatory risk in exchange for platform-scale potential.
Vertex’s CASGEVY expansion to patients as young as 2 looks like a real commercial runway extension, not a cosmetic label update. With elite margins, strong growth, and a TickerSpark Score of 89, the stock still looks built for more than a one-day pop.
Moderna’s latest surge looks earned, not speculative. Science Day gave the market a concrete post-COVID roadmap, and the August 5 flu decision gives MRNA a real catalyst investors can actually underwrite.
Axsome has evolved into a commercial CNS growth story, led by AUVELITY’s rapid prescription gains and a newly expanded Alzheimer’s agitation opportunity. The stock looks attractive on execution, but valuation and ongoing losses keep it from being a low-risk idea.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator